前收市價 | 12.48 |
開市 | 12.47 |
買盤 | 12.31 x 800 |
賣出價 | 12.76 x 900 |
今日波幅 | 12.45 - 12.56 |
52 週波幅 | 3.00 - 13.66 |
成交量 | |
平均成交量 | 74,330 |
市值 | 178.679M |
Beta 值 (5 年,每月) | 1.80 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.12 |
業績公佈日 | 2023年8月02日 - 2023年8月07日 |
遠期股息及收益率 | 無 (無) |
除息日 | 2019年12月13日 |
1 年預測目標價 | 4.00 |
In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]
Ipsen SA (OTC: IPSEY) announced that the Phase 3 NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint. The combination therapy demonstrated a clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Progression-free survival (PFS) also showed significant improvement ov
Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. The safety and tolerabilit